Optimising Treatment of HF
Published: 21 April 2021
-
Views:
18435
-
Likes:
7
Overview
Full programme
-
Views:
18435
-
Likes:
7
PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
Overview
Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.
Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).
Learning objectives
- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
Audience
- Heart Failure Specialists
- General Cardiologists
- Nurses
- Allied Health Professionals
More from this programme
Part 1
PART 1 – Introduction – Optimising Treatment of HF
Part 2
PART 2 – A Review of Recent SGLT2 Inhibitor Data
Part 3
PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
Part 4
PART 4 – Existing HF-REF: Augmenting the SOC
Part 5
PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?
Faculty Biographies

Javed Butler
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Dallas, TX and Professor of Medicine, University of Mississippi, Jackson, MS, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He has authored more than 900 peer-reviewed publications.